Pharma Gears Up for Pricing Battle as Democrats Scale Back Legislation

Democrats are gradually reducing the scope of legislation intended to reduce drug prices. The pharmaceutical industry has voiced its opposition to any policies limiting price tags, including legislation granting Medicare the power to negotiate drug costs. The final outcome remains uncertain.

“Industry groups like PhRMA have consistently argued that allowing the government to negotiate drug prices would hamper access and innovation, especially in light of the life-saving development of COVID-19 vaccines in the last year.” Read more here.

(Source: Lecia Bushak, MM+M, 10/28/21)